AXSM
Axsome Therapeutics Inc.
$134.99
+$1.84(+1.38%)
51
Overall
40
Value
63
Tech
--
Quality
Market Cap
$5.79B
Volume
508.23K
52W Range
$75.56 - $139.13
Target Price
$176.89
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | $50.0M | $270.6M | $385.7M | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | $50.0M | $270.6M | $385.7M | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $5.2M | $26.1M | $33.3M | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | $44.8M | $244.5M | $352.4M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-27.5M | $-27.2M | $-32.8M | $67.2M | $99.1M | $124.7M | $221.3M | $427.4M | $604.8M | ||
| Research & Development | $21.2M | $20.0M | $23.5M | $53.6M | $70.2M | $58.1M | $57.9M | $97.9M | $187.1M | ||
| Research Expense | $21.2M | $20.0M | $23.5M | $53.6M | $70.2M | $58.1M | $57.9M | $97.9M | $187.1M | ||
| Selling, General & Administrative | $6.3M | $7.2M | $9.4M | $13.6M | $28.9M | $66.6M | $159.3M | $323.1M | $411.4M | ||
| General & Administrative Expenses | $6.3M | $7.2M | $9.4M | $13.6M | $28.9M | $66.6M | $159.3M | $323.1M | $411.4M | ||
| Salaries & Wages | $-2.0M | $-2.1M | $-1.8M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | $4.1M | $6.4M | $6.4M | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | $4.1M | $6.4M | $6.4M | ||
| Amortization | $-68.9K | $-470.5K | $-375.6K | $650.0K | $786.8K | $1.1M | $4.1M | $6.4M | $6.4M | ||
| Other Operating Expenses | -- | -- | $-32.8M | $67.2M | $870.3K | $1.2M | -- | -- | -- | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-27.5M | $-27.2M | $-32.8M | $-67.2M | $-99.1M | $-124.7M | $-179.8M | $-231.8M | $-280.6M | ||
| EBITDA | $-27.6M | $-28.6M | $-31.5M | $-66.4M | $-100.3M | $-124.6M | $-181.3M | $-228.9M | $-276.5M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $2.6M | $5.7M | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-132.4K | $-1.3M | $-1.1M | -- | -- | -- | -- | -- | -- | ||
| Gain on Sale of Securities | -- | -- | -- | $-1.2M | $-2.6M | $-5.7M | $-7.3M | $-6.5M | $-6.6M | ||
| Other Income/Expense | -- | $646.0K | $-2.8M | $1.2M | $3.8M | $5.7M | $7.3M | $6.5M | $6.6M | ||
| Other Special Charges | -- | $-646.0K | $2.8M | -- | $-1.2M | -- | -- | -- | -- | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | $211.6M | -- | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | $-211.6M | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-27.7M | $-29.2M | $-31.9M | $-67.1M | $-100.3M | $-124.7M | $-187.1M | $-238.3M | $-287.1M | ||
| Pre-Tax Income | $-27.7M | $-29.2M | $-31.2M | $-68.5M | $-103.0M | $-130.4M | $-187.1M | $-238.3M | $-287.1M | ||
| INCOME TAX | |||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | $960.0K | $85.0K | ||
| NET INCOME | |||||||||||
| Net Income | $-27.2M | $-28.9M | $-31.0M | $-68.3M | $-102.9M | $-130.4M | $-187.1M | $-239.2M | $-287.2M | ||
| Net Income (Continuing Operations) | $-27.2M | $-28.9M | $-31.0M | $-68.3M | $-102.9M | $-130.4M | $-187.1M | $-239.2M | $-287.2M | ||
| Net Income (Discontinued Operations) | $-27.2M | $-28.9M | $-31.0M | $-68.3M | $-102.9M | $-130.4M | $-187.1M | $-239.2M | $-287.2M | ||
| Net Income (Common Stockholders) | $-27.2M | $-28.9M | $-31.0M | $-68.3M | $-102.9M | $-130.4M | $-187.1M | $-239.2M | $-287.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-284.3M | ||
| TOTALS | |||||||||||
| Total Expenses | $-27.5M | $-27.2M | $-32.8M | $67.2M | $99.1M | $124.7M | $226.5M | $453.5M | $638.1M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $19.2M | $22.8M | $26.9M | $34.0M | $37.2M | $37.6M | $40.7M | $45.4M | $47.9M | ||
| Average Shares Outstanding (Diluted) | $19.2M | $22.8M | $26.9M | $34.0M | $37.2M | -- | $40.7M | $45.4M | $47.9M | ||
| Shares Outstanding | $19.2M | $25.5M | $33.3M | $37.1M | $37.4M | $38.5M | $43.5M | $47.4M | $48.8M | ||
| Basic EPS | -- | -- | -- | $-2.01 | $-2.77 | $-3.47 | $-4.6 | $-5.27 | $-5.99 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-2.01 | $-2.77 | $-3.47 | $-4.6 | $-5.27 | $-5.99 | ||
| Diluted EPS | $-1.42 | $-1.27 | $-1.15 | $-2.01 | $-2.77 | $-3.47 | $-4.6 | $-5.27 | $-5.99 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-4.6 | $-5.27 | $-5.99 | ||
| OTHER METRICS | |||||||||||
| Interest Expense Operating | -- | -- | $-751.7K | $1.4M | $2.4M | $4.6M | -- | -- | -- | ||
| Net Income From Other Gains Losses | $474.3K | $207.1K | $217.4K | $139.4K | $53.6K | -- | -- | -- | -- | ||
| Other Gand A | $6.3M | $7.2M | $9.4M | $13.6M | $28.9M | $66.6M | $159.3M | $323.1M | $411.4M | ||
| Rent And Landing Fees | $6.3M | $7.2M | $9.4M | $485.5K | $870.3K | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | $211.6M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AXSM | $134.99 | +1.4% | 508.23K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Axsome Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW